Compare CRSP & SWX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | SWX |
|---|---|---|
| Founded | 2013 | 1931 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.9B |
| IPO Year | 2016 | 2017 |
| Metric | CRSP | SWX |
|---|---|---|
| Price | $50.20 | $88.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 10 |
| Target Price | $85.63 | ★ $99.78 |
| AVG Volume (30 Days) | ★ 1.5M | 540.1K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 2.99% |
| EPS Growth | N/A | ★ 120.29 |
| EPS | N/A | ★ 2.49 |
| Revenue | $289,590,000.00 | ★ $5,433,972,000.00 |
| Revenue This Year | $1,052.09 | N/A |
| Revenue Next Year | $273.88 | $6.24 |
| P/E Ratio | ★ N/A | $34.85 |
| Revenue Growth | ★ 9169.85 | 9.56 |
| 52 Week Low | $44.12 | $76.99 |
| 52 Week High | $70.74 | $94.47 |
| Indicator | CRSP | SWX |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 57.27 |
| Support Level | $45.61 | $83.99 |
| Resistance Level | $60.71 | $89.83 |
| Average True Range (ATR) | 2.51 | 1.46 |
| MACD | -0.48 | 0.72 |
| Stochastic Oscillator | 8.96 | 84.31 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.